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The Southeastern United States has the highest prevalence of hypertension and 
African Americans have disproportionately worse blood pressure control. The authors 
sought to evaluate the effect of a multicomponent practice- based quality improve-
ment intervention on lowering mean systolic blood pressure (SBP) at 12 and 24 months 
compared with baseline among 525 patients, and to assess for a differential effect of 
the intervention by race (African Americans vs white). At 12 months, both African 
Americans (−5.0 mm Hg) and whites (−7.8 mm Hg) had a significant decrease in mean 
SBP compared with baseline, with no significant between- group difference. Similarly, 
at 24 months, mean SBP decreased in both African Americans (−6.0 mm Hg) and 
whites (−7.2 mm Hg), with no significant difference between groups. Notably, no 
significant racial disparity in mean SBP at baseline was shown. The intervention was 
effective in lowering mean SBP in both African Americans and whites but there was no 
differential effect of the intervention by race.
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1  | BACKGROUND
Hypertension (HTN) affects more than 80 million persons in the 
United States1 and increases the risk of all- cause mortality and mortal-
ity due to coronary heart disease, stroke, end- stage renal disease, and 
heart failure.2 The Southeastern United States has the highest preva-
lence of HTN.3 Racial differences in HTN prevalence and control are 
persistent,4 with African Americans (AAs) having among the highest 
prevalence of HTN in the world and poor rates of control.5 Given the 
excess morbidity and mortality associated with poorly controlled HTN 
in AAs, it is imperative to identify interventions that improve blood 
pressure (BP) control among this population, particularly those in the 
Southeast.
Contributors to BP control exist at multiple levels along the so-
cioecological framework,6 including the individual level (eg, literacy, 
medication adherence), the patient- provider interaction level (eg, 
communication), and the organizational/practice level (eg, clinical 
decision support). Therefore, interventions to improve BP control 
should be designed and implemented with attention to addressing 
multilevel determinants, including using strategies that have been 
shown to improve BP control in racial/ethnic minorities.6–9 In partic-
ular, team- based care, patient education, facilitated relay of clinical 
data, supported self- management, home BP monitoring, and health 
coaching have demonstrated effectiveness in controlling BP.7,10
This study evaluated the effect of a multicomponent practice- 
based quality improvement (QI) intervention on lowering systolic BP 
(SBP) in a cohort of patients selected on having uncontrolled HTN as 
measured at their practice. We also aimed to determine whether the 
intervention would have a differential effect by race. We hypothe-
sized that the intervention would reduce mean SBP at both 12 and 
24 months overall and that AA patients would have greater improve-
ment in lowering SBP compared with white patients, based on our in-
clusion of strategies that have been shown to be particularly effective 
in racial/ethnic minorities.
2  | METHODS
2.1 | Study design and setting
We conducted a prospective cohort study (2010–2015) involving 
525 adults with HTN across six primary care practices in Lenoir 
County, a poor, economically distressed county in eastern North 
Carolina. Lenoir County has more residents living below the federal 
poverty level than the rest of the state and, in 2007, 23% of the 
residents were eligible for Medicaid, compared with 15% for the 
state.11
The sites included three private practices, a hospital- owned prac-
tice, and two community health centers. The practices varied in size 
from single- provider practices to multispecialty group practices. Study 
recruitment occurred from October 2011 to October 2012 with fol-
low- up completed in October 2014. We used a nonrandomized ob-
servational trial design to maximize feasibility and acceptability for 
conducting this research in busy rural primary care practices unaccus-
tomed to participating in research and to facilitate broad community 
participation.12 Detailed information on the study design and methods 
has been previously published in a study protocol paper.13,14 Briefly, 
the study included a formative phase, where we collected data from 
41 in- depth interviews with patients, providers, and staff (68.5% were 
AA, 7.3% were American Indian, and 7.3% were mixed race) to assess 
their perceptions of resources and barriers that influence HTN control 
in their region.14 During the implementation phase of this study, we 
conducted a practice- based intervention using a QI approach, with 
strategies designed to change practice and patient behavior (outlined 
in Table 1).
2.2 | Participants
Working collaboratively with practice staff, we identified and re-
cruited potentially eligible patients. Inclusion criteria were English- 
speaking patients from participating practices with an established 
HTN diagnosis and at least one visit in the last year with an office 
measurement of SBP ≥150 mm Hg. For most of the practices, BP 
was measured by medical assistants or licensed practical nurses. 
To attempt to optimize our ability to find participants with uncon-
trolled BP when measured using guideline- supported techniques 
(the Seventh Report of the Joint National Committee on Prevention, 
Detection, Evaluation, and Treatment of High Blood Pressure), we se-
lected a study referral SBP cutoff value of 150 mm Hg, based on data 
suggesting that BP readings obtained using guideline- recommended 
techniques are lower, on average by 12.4 mm Hg systolic, than those 
obtained in using usual care processes.15 For enrolled study partici-
pants, BP measurement was obtained by trained research staff at a 
community- based data collection site. We did not assess for or ex-
clude individuals with white- coat HTN. Eligible participants provided 
written informed consent.
This study was funded by the National Institutes of Health (NIH)/
National Heart, Lung, and Blood Institute as part of the Centers for 
Population Health and Health Disparities. This study was approved by 
the institutional review board at the University of North Carolina at 
Chapel Hill and is registered on clinicaltrials.gov (NIH study registry 
number NCT01425515).
2.3 | Intervention components
We used a participatory approach to intervention development, en-
gaging the providers and staff of the participating practices. Briefly, 
our multicomponent, theory- driven intervention included strategies 
at the practice/organization and the patient levels. We adapted the 
Promoting Action on Research Implementation in Health Services 
(PARIHS) model for the practice- level intervention, to conceptualize 
practice change.16 The practices and the community- based health 
coach were taught communication and behavior change strategies 
based on social cognitive theory,17 the transtheoretical model of be-
havior change, and motivational interviewing.18,19 Table 1 summarizes 
the intervention components. The telephone coaching part of our 
intervention was informed by components of Bosworth’s Take Care 
of Your Blood Pressure (TCBY) study,20 which included telephone 
case management. Investigators from Bosworth’s study helped our 
team develop the phone coaching software and train our coaches. 
We used two trained health coaches (non- nurses) who were external 
to the practice and were trained in motivational interviewing.19 The 
lead coach was a certified integrative health coach. He also received 
a 4- hour training session on the telephone management program and 
participated in follow- up phone calls to discuss challenges with imple-
mentation. The lead coach trained the second coach. Additional de-
tails on the health coaching, including our assessment of fidelity to the 
health coaching intervention, is in press.21 The coaches delivered the 
intervention via 12 monthly phone calls that lasted 15 to 20 minutes 
each. The coaches helped participants set care goals, reviewed appro-
priate BP measurement techniques, and discussed BP target values on 
each phone call. Participants were also mailed educational materials to 
correspond to the topics of each upcoming phone coaching session. A 
manuscript with additional descriptions of and lessons learned from 
implementing the phone coaching component of this intervention is 
currently in press.21
2.4 | Data sources/measurement
We collected data at baseline and at 6, 12, 18, and 24 months post- 
enrollment. Instruments used for data collection have been outlined in 
a previous publication.13 All outcomes measure assessment was done 
by trained research staff using measurements obtained at research 
study visits, not part of routine clinical care.
2.5 | BP and race
BP was measured by trained research staff using the Omron HEM- 
907 automated BP monitor (Omron Healthcare, Inc, Vernon Hills, IL). 
A research assistant (RA) recorded the average of three sequential 
measurements obtained at 60- second intervals after the participant 
was seated for 5 minutes with both feet on the floor.22,23





• Use of population-level hypertension (HTN) data to drive change and 
enhance quality
• Strategies for systematizing care for all HTN patients (eg, identifying 
blood pressure [BP] goals, assessing BP knowledge, and using and 
reviewing home BP monitoring readings)
• Medication adherence
• Case study presentations—challenging cases and treatment options
• Phone coaching, motivational interviewing techniques, and goal setting
• Importance of health literacy for BP control, including explanation and 
demonstration of strategies (eg, videos and role play) to support patients 





• Define HTN population and abstract and review HTN control data from 
the EHR
• Instruction on accurate BP measurement
• Design and use of visit planners
• Design and use of HTN medication algorithm
Throughout study with assistance from practice 
facilitators (ie, members of the research team) 
who visited practices regularly and via monthly 
“design team” conference calls with practice 
providers, staff, and research team
Patient- level strategies (for all 525 patients in the cohort)
Phone coaching • Benefits of BP medication, medication adherence, side effects, strategies 
to enhance adherence
• Strategies to enhance communication with healthcare providers
• Strategies for incorporating physical activity into one’s lifestyle and 
mitigating barriers to physical activity
• Healthy eating: reading food labels, understanding salt reduction, 
Dietary Approaches to Stop Hypertension (DASH) diet, portion control
• Home BP measurement: accurate measurement technique, reviewing 
recent BP readings, addressing BP goals/targets




• All patients were given automated, oscillometric home blood pressure 
monitors at study enrollment.
• Patients were instructed to measure and record their BP three times per 
week and to bring their records to every primary care and research clinic 
visit.
• Primary care physicians were encouraged to review and reinforce the 
value of home monitoring.
Throughout study
Race was self- reported with categories consistent with the US 
Census.
2.6 | Covariates
Other self- reported covariates of interest included age, sex, educa-
tional level, employment status, health insurance coverage (includ-
ing Medicare, Medicaid, commercial insurance), annual household 
income, current cigarette smoking, taking antihypertensive medica-
tions, antihypertensive medication nonadherence (assessed using the 
8- item Morisky Medication Adherence Scale),24 and comorbidities.
We assessed diabetes based on self- report of physician- diagnosed di-
abetes or hemoglobin A1c ≥6.5. We also measured literacy level using 
the Short Test of Functional Health Literacy Assessment (STOFHLA)25 
and measured height and weight (to calculate body mass index).
2.7 | Lifestyle study
Thirty- eight percent of study participants were simultaneously en-
rolled in a community- based lifestyle and weight loss intervention 
given that individuals with HTN are at increased risk for cardiovascular 
disease and may benefit from receiving a lifestyle intervention. Briefly, 
the lifestyle study began with a 4- month intervention phase focused 
on improving dietary fat and carbohydrate quality and increasing 
physical activity. During the remainder of the 2- year intervention, 
participants with a body mass index ≥25 kg/m2 were invited to take 
part in a weight loss intervention. Findings from that study, including 
effects of the lifestyle intervention on SBP, have been published.26
2.8 | Analyses
The primary aim of the study was to evaluate the effectiveness of 
the intervention on average SBP at 12 and 24 months overall and by 
race (AAs vs whites). Seven participants were excluded from the race- 
stratified analysis because they were categorized as “other” race. We 
also examined the proportion of the sample that achieved BP con-
trol (BP <140/90 mm Hg) at each time point (Figure 2). Our sample 
size calculation was based on detecting a difference in mean SBP of 
3.5 mm Hg between AAs and white patients using a one- sided .05 t 
test, assuming a baseline mean difference in SBP between AAs and 
whites of approximately 5 mm Hg.
We used descriptive statistics to summarize the sample character-
istics overall and by race and compared participant characteristics by 
race using chi- square test for categorical variables and t test for con-
tinuous variables. The overall effect of the intervention on reducing 
SBP at 12 and 24 months was tested using a paired t test. We com-
pared mean changes in SBP between AAs and white patients using 
simple linear regression and multivariable regression controlling for 
age, sex, co- enrollment in the lifestyle study, and other covariates that 
were imbalanced between the races (educational level, diabetes, and 
weight). We did not adjust for household income as it was highly cor-
related with educational level and was not reported by 15% of study 
participants.
We conducted the analyses with the intent- to- treat (ITT) prin-
ciple by imputing missing SBP data using the last- observation- 
carried- forward approach, as well as conducting the analyses on only 
participants with nonmissing outcome data for the time period of 
interest. As results were qualitatively the same, we report outcomes 
for returnees only in the main text but results for ITT analyses are 
included as Supporting Information.
We also conducted longitudinal analyses using generalized linear 
mixed models that included a random intercept to account for within- 
subject correlation over time and with race and time as fixed effects, 
to examine changes over time and to assess changes in SBP at 12 
and 24 months. Because the results were similar to results obtained 
using paired t tests and linear regressions at single time points, we do 
not present the results from longitudinal models. Analyses were con-
ducted using SAS software, version 9.3 (SAS Institute Inc, Cary, NC).
Finally, we conducted sensitivity analyses, including stratifying 
our primary analyses based on: (1) co- enrollment in a lifestyle study 
(Tables S5 and S6), and (2) having an SBP at baseline of ≥140 mm Hg.
Because we did not find significant differences in SBP by race 
when comparing practice as a fixed vs a random effect (P=.08), we did 




We enrolled 525 participants across six practices. Figure 1 shows the 
participant flow diagram for the study. Overall, the mean age of our 
sample was 58 years, and the majority of participants were female 
with a high school or less education (Table 2). Twenty- three percent 
of the sample had an STOFHLA score in the “low literacy” category. 
Most of the participants (75%) had health insurance. Forty- three per-
cent of the overall sample had diabetes, based on either self- report or 
hemoglobin A1c ≥6.5. Twenty- three percent were current smokers. At 
baseline, mean systolic and diastolic BP was 139 mm Hg and 82 mm 
Hg, respectively. Notably, there was no significant racial difference 
in SBP at baseline, with AAs having a mean SBP of 140 mm Hg and 
whites having a mean SBP of 137 mm Hg (P=.25). Most participants 
(89%) reported taking antihypertensive medications (mean of 1.9 
medication classes) at baseline. Thirty- eight percent of the overall 
sample was also concurrently enrolled in a lifestyle intervention study.
3.2 | Effect of intervention on mean change in SBP 
at 12 and 24 months
After examining the differences in baseline characteristics between 
attendees and nonattendees at 12- and 24- month follow- up visits, we 
found that attendees were more likely than nonattendees to be older, 
AA, and have moderate- high medication adherence.
At 12 months compared with baseline, mean SBP was 6 mm Hg 
lower for the overall sample in unadjusted analyses (Table 3). Both 
AAs (−5.0 mm Hg) and whites (−7.8 mm Hg) had a significant decrease 
in mean SBP (both P values <.001), but the unadjusted difference in 
the changes in SBP between the races was not statistically significant 
(−2.7 mm Hg, P=.26). After multivariable adjustment, the difference in 
the changes in mean SBP between race groups remained small and not 
statistically significant.
Table 4 presents the differences in mean SBP from baseline to 
24 months overall and by race. Mean SBP decreased by 6.4 mm Hg 
overall. Similar to the baseline to 12 month comparisons, mean SBP 
decreased in both AAs and whites, but the unadjusted between- race 
difference in mean SBP change was small and not statistically signif-
icant (−1.3 mm Hg, P=.61). The adjusted differences in mean SBP 
change by race remained nonsignificant after multivariable adjustment.
The corresponding results based on ITT analysis are presented in 
Tables S1 and S2.
We also conducted a longitudinal analysis examining SBP changes 
from 0 to 6, 6 to 12, 12 to 18, and 18 to 24 months (data not shown). 
This analysis demonstrated that the greatest reduction in SBP oc-
curred during the first 12 months (P<.01 for both the 0 to 6 months 
and 6 to 12 months time periods) and the trend was similar in AAs and 
whites.
3.3 | Effect of intervention on changes in SBP among 
those co- enrolled in a lifestyle study
Tables S3 and S4 in the Supporting Information present data on ra-
cial differences in SBP from baseline to 12 months and baseline to 
24 months within strata of co- enrollment in the lifestyle study. Among 
those not co- enrolled in the lifestyle study, the racial difference in SBP 
change was −5.7 (−11.1 to −0.2), slightly favoring whites (P=.04) in the 
unadjusted analysis. Among those who were co- enrolled in the life-
style study, the racial difference in SBP change was 1.5 (−7.5 to 10.4) 
in the unadjusted analysis. The data on racial differences in SBP from 
baseline to 24 months within strata of co- enrollment in the lifestyle 
study were similar to the data for 12 months.
Corresponding results based on ITT analysis are presented in 
Tables S3 and S4.
3.4 | Effect of intervention on changes in SBP among 
those with baseline SBP ≥140 mm Hg
Among participants who returned for 12- month follow- up, 183 
participants (66 whites, 117 AAs) had a baseline SBP ≥140 mm Hg, 
with an overall mean SBP of 158 mm Hg (156 to 159 mm Hg). At 
12 months, the mean SBP for the overall sample was 141 mm Hg 
(138 to 144 mm Hg). While both AAs and whites had highly signifi-
cant reductions in mean SBP from baseline to 12 months (mean for 
AAs, 15.3 mm Hg; mean SBP for whites, 17.4; both P values <.0001), 
the between- race difference in mean BP change was not statistically 
significant (P=.6). Among participants who returned for 24- month fol-
low- up (175 participants; 62 whites, 113 AAs) the results were similar 
(data not shown).
3.5 | Effect of intervention on achieving BP control 
(<140/90 mm Hg) at 12 and 24 months
Figure 2 presents the percentage of patients with controlled BP at 
each time period. At baseline, 55% of the overall sample had con-
trolled BP (54% AAs and 56% whites). At 12 months, 70% of the 
overall sample had controlled BP. Of those who were uncontrolled 
at baseline (n=183), 56% were controlled at 12 months and this 
F IGURE  1 Study flow diagram. *Other race included mixed 
race, those who identified race as Hispanic or human, and those 
who refused to identify. †Withdrawals were due to death, medical 
reasons, moved out of area, requested to stop participation, personal 
reasons, lost to follow- up, or other reason. ‡Exclusions for analysis 
were due to diagnosis of cancer, gastric bypass surgery, gastric sleeve 
surgery, and pregnancy
significantly differed by race (62% of whites vs 52% of AAs, P<.0001). 
At 24 months, 54% of the overall sample had controlled BP. Of those 
who were uncontrolled at baseline (n=175), 59% had controlled BP at 
24 months and this was significantly different by race (56% of whites 
vs 61% of AAs, P<.0001).
4  | DISCUSSION
Our study suggests that a multicomponent, multilevel intervention 
delivered in rural primary care practice can lower SBP over a 2- year 
period among AA and white patients with HTN. Although our inter-
vention included both practice- and individual- level strategies that 
have been shown to improve BP control in racial/ethnic minority 
groups, our intervention was not differentially more effective in AAs 
than whites.
Contrary to what we expected based on most extant data, we did 
not see a racial disparity in SBP at baseline. On the contrary, BP was 
fairly well- controlled (mean SBP 139 mm Hg overall) with no signif-
icant differences in mean SBP by race, using standard BP measure-
ments obtained at study visits by trained research staff. Similar studies 









Age, mean (range) 58 (20–93) 57 (25–93) 60 (22–91) .02
Female sex 356 (68) 218 (71) 134 (63) .05
Education: high school or less 382 (73) 246 (80) 132 (62) <.001
Low literacy
STOFHLA score=0–22 (6% missing) 111 (23) 85 (30) 25 (12) <.001
Currently have health insurance 394 (75) 218 (71) 170 (80) .02
Employment status
Working full or part time 199 (38) 120 (39) 74 (35) .32
Household income ≤$40,000  
(15% missing)
350 (78) 224 (88) 121 (66) <.001
Self- rated health (good–excellent) 322 (61) 187 (61) 130 (61) .96
CVD and risk factors for CVD
CVD 122 (23) 69 (23) 52 (25) .60
Diabetes 227 (43) 154 (50) 70 (33) <.001
Current cigarette smoker 118 (23) 69 (23) 47 (22) .54
Systolic BP, mean (SE), mm Hg 139 (1.0) 140 (1.3) 137 (1.4) .25
Diastolic BP, mean (SE), mm Hg 82 (0.6) 83 (0.8) 80 (0.8) .01
Systolic BP ≥140 mm Hg 231 (44) 138 (45) 89 (42) .48
Medication class count, mean (SE) 
(4% missing)
1.9 (.01) 2.1 (0.1) 1.6 (0.1) <.001
Antihypertensive medication adherence
Low (Morisky score <6) (11% missing) 187 (40) 128 (42) 58 (34) .05
Lifestyle
Lifestyle study participant 200 (38) 130 (42) 72 (34) .07
Physiologic mean (SE)
Weight, kg (1% missing) 98 (1.2) 102 (1.5) 93 (1.8) <.001
BMI (2% missing) 36 (0.4) 37 (0.6) 34 (0.6) <.001
No. of comorbidities, mean (SE)b 3.5 (0.1) 3.4 (0.1) 3.7 (0.2) .04
Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters 
squared); BP, blood pressure; CVD, cardiovascular disease; HbA1c, hemoglobin A1c; SE, standard error; 
STOFHLA, Short Test of Functional Health Literacy Assessment.
Data are reported as number (percentage) of participants unless otherwise indicated.
aSeven not categorized (one mixed race, two erroneous, four refused).
bComorbidities include heart failure, high blood pressure or hypertension, high cholesterol, chronic ob-
structive pulmonary disease, kidney disease, lung disease, stroke or mini- stroke, depression, chronic back 
pain, cancer, diabetes, arthritis, fibromyalgia, and obstructive sleep apnea.
TABLE  2 Baseline Participant 
Characteristics
hypertensive patients when measured by trained research staff.27 
There is a very plausible reason for these findings. We targeted pa-
tients for enrollment who had a previously documented in- clinic SBP 
≥150 mm Hg, as measured by clinic staff. It is likely that this level of 
BP was an overestimate of the patient’s “true” SBP given that prior 
studies have noted limitations of office BP measurement, including 
low reproducibility and difficulty in obtaining high- quality and accurate 
measurement.28,29 Together, these factors resulted in our enrolling a 
sample with much better BP control than we expected. Moreover, the 
near- normal BP readings at baseline limited our ability to demonstrate 
effectiveness of the intervention and show superior outcomes among 
AAs. Although we did not see a differential effect of the intervention 
in AAs, the fact that we successfully engaged AAs is, in and of itself, 
a success. Fifty- eight percent of the sample was AA, with almost 30% 
being AA men—a group that generally has less physician contact than 
other groups, lower rates of HTN treatment and control, and are often 
felt to be more difficult to engage and enroll in research studies.1,30,31
The overall effect sizes noted in our study (−6.0 mm Hg at 
12 months and −6.4 mm Hg at 24 months) are consistent with pub-
lished estimates from a systematic review of QI strategies for HTN 
management.7 In that review, intervention groups experienced me-
dian reductions in SBP that were 4.5 mm Hg (interquartile range, 1.5 
to 11.0) greater than control groups. We can directly compare our 
findings with those from two other multilevel, multicomponent in-
terventions that have examined intervention effects on reducing ra-
cial disparities in BP.32,33 Jackson and colleagues32 conducted a post 
hoc analysis of data from a randomized clinical trial conducted in the 
Veterans Affairs healthcare system, which tested interventions consist-
ing of home BP monitoring plus medication management with clinical 
decision support, home BP monitoring plus a behavioral management 
intervention, or a combined medication management and behavioral 
management intervention against usual care. This study demonstrated 
differential intervention effects on SBP over time for AAs and whites, 
with AAs benefiting from the intervention while whites observed no 
TABLE  3 Mean Change in SBP at 12 Months, Overall and By Race
























SBP, mm Hg (95% CI)
Overall 408 139 (137–141) 133 (131–135) 6.0 (4.1–8.0)
P<.01
AAs 257 139 (137–142) 134 (132–137) 5.0 (7.6–2.5)
P<.01
−2.7 (−7.5 to 
2.0)
−1.7 (−6.5 to 
3.0)
−2.1 (−6.8 to 
2.6)
−3.4 (−7.7 to 
0.9)
Whites 151 138 (135–140) 130 (127–133) 7.8 (10.6–4.9)
P<.001
Abbreviations: AAs, African Americans; CI, confidence interval; SBP, systolic blood pressure.
aModel adjusted for age and sex.
bModel adjusted for age, sex, and co- enrollment in the lifestyle study.
cModel adjusted for age, sex, co- enrollment in the lifestyle study, education level, diabetes, weight, and health insurance.
TABLE  4 Mean Change in SBP at 24 Months, Overall and By Race
Group No. Baseline 24 Months























SBP, mm Hg (95% CI)
Overall 383 139 (137–141) 133 (131–135) −6.4 (8.3–4.4)
P<.001
AAs 246 140 (137–142) 134 (132–136) 6.0 (8.5–3.3)
P<.001
−1.3 (−6.1 to 
3.6)
0 (−4.8 to  
4.8)
−0.5 (−5.3 to 
4.4)
−2.0 (−6.1 to 
2.0)
Whites 137 138 (136–141) 131 (129–134) 7.2 (10.0–4.3)
P<.001
Abbreviations: AAs, African Americans; CI, confidence interval; SBP, systolic blood pressure.
aModel adjusted for age and sex.
bModel adjusted for age, sex, and co- enrollment in the lifestyle study.
cModel adjusted for age, sex, co- enrollment in the lifestyle study, education level, diabetes, weight, and health insurance.
benefit. AAs in the combined intervention group, compared with the 
usual care group, had significantly lower SBP at 12 months (−6.6 mm 
Hg; 95% confidence interval, −12.5 to −0.7) and 18 months (−9.7 mm 
Hg; 95% confidence interval, −16.0 to −3.4).
In another post hoc analysis, Bosworth and colleagues33 compared 
the effects of several interventions (home BP monitoring, behavioral 
phone calls without medication management, and a combination of 
the two) with usual care among white and predominantly AA (95%) 
patients. The race by time by treatment effect suggested likely differ-
ential intervention effects over time in SBP for whites and nonwhite 
patients (P=.08). At 12 months, nonwhite participants in all three in-
tervention groups had SBP decreases of 5.3 mm Hg to 5.7 mm Hg 
compared with usual care (all P<.05). At 24 months, nonwhite patients 
in the combined intervention arm continued to have lower SBP com-
pared with the usual care group (7.5 mm Hg, P<.02). Among whites, 
mean SBP was not significantly different at 12 and 24 months for in-
tervention arm patients compared with usual care patients.
Other studies have also tested practice- based interventions 
with intervention strategies primarily targeted at patients and physi-
cians.20,34–36 The effects on BP of these multicomponent interventions 
is mixed. Unlike our study, all of these studies except for one35 used a 
randomized trial design, most enrolled a majority or exclusively racial 
minority population, and therefore did not examine differential inter-
vention effects by race.
We propose two possible explanations for why our interven-
tion was not differentially more effective in AAs than whites. First, 
our intervention was a practice- level QI intervention that employed 
strategies that have been associated with BP improvement in racial 
minority populations, such as supported self- management, home BP 
monitoring, continuing medical education, practice facilitation, and 
team- based HTN care7,10,37–41; however, we did not culturally tailor 
our intervention to AAs. Previous research has shown that QI strat-
egies can be effective in improving SBP42,43; however, the effects of 
generalized QI programs on disparities reduction have found mixed 
results.44,45 Some studies have shown a reduction in disparities in 
processes of care with little effect on disparities in clinical outcomes. 
Second, our patient- level intervention may not have sufficiently 
addressed the unique factors that influence BP in AAs. Studies have 
demonstrated that there may be racial differences in patterns of inter-
action within the healthcare system,46 psychosocial and cultural fac-
tors,46 and disease- perception issues (eg, beliefs about HTN).47 These 
factors may have differential effects on SBP in AAs compared with 
whites and our intervention did not target these contributors to BP 
control.
5  | STUDY LIMITATIONS AND STRENGTHS
Our study’s findings should be considered in light of its limitations. 
First, as a cohort study reporting pre- post measures, observed 
changes could be due to secular trends or other factors and not the 
intervention per se. Second, our missing data rate of about 25% at 
each time period may have biased our results. However, we were 
more likely to retain AAs—a population that many researchers have 
deemed “hard to recruit and retain”—than whites. Third, the QI na-
ture of our study was a limitation and a strength. We designed and 
implemented the intervention with broad stakeholder input to maxi-
mize feasibility and sustainability.14 However, the level of engage-
ment with the intervention was inconsistent and variable across the 
six practices. Issues such as staff turnover and practices’ novelty 
in participating in research may have adversely impacted interven-
tion delivery. Fourth, we have several limitations with respect to 
BP assessment. We used only a single elevated SBP as the enroll-
ment criteria. We did not use ambulatory BP monitoring to screen 
participants for HTN, as this was not a US Preventive Task Force 
Grade A recommendation at the time this study was designed and 
implemented. Last, the “bundled” nature of our intervention makes 
it difficult to discern which components of the intervention were the 
most beneficial.
Despite these limitations, our study has strengths. We focused 
exclusively on a rural impoverished community where the burden 
of HTN is high, whereas other studies have focused on more urban 
populations.32,33 Second, our study was specifically powered to assess 
effect modification by race, unlike other studies that conducted post 
F IGURE  2 Percentage of patients with 
controlled blood pressure (<140/90 mm 
Hg), overall and by race, at baseline and at 
12- and 24- month follow- up
hoc analyses by race32,33 or that did not examine race differences in 
intervention effects.48
6  | CONCLUSIONS
Our study demonstrates that we can reduce mean SBP and improve 
BP control among AA and white patients with HTN from rural un-
derserved communities through a systematic practice- based QI in-
tervention. However, our intervention is not more effective in AAs 
compared with whites. Surprisingly, we did not show a racial disparity 
in SBP at baseline and baseline SBP of the sample was fairly well con-
trolled when measured by trained research staff outside of the clinical 
encounter. This highlights well- known issues with approaches to BP 
measurement and the disparity of HTN control in daily practice com-
pared with clinical trials.49,50
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